Supplementary Table 3. Absence of MBS by Timepoint (mITT Population): ACHIEVE I and ACHIEVE II

	ACHIEVE I							ACHIEVE II						
	Placebo	Ubrogepant 50 mg			Ubrogepant 100 mg			Placebo	Ubrogepant 25 mg			Ubrogepant 50 mg		
Hours Post Dose	n/N1	n/N1	Odds Ratio (95% CI)	P-value	n/N1	Odds Ratio (95% CI)	P-value	n/N1	n/N1	Odds Ratio (95% CI)	P-value	n/N1	Odds Ratio (95% CI)	P-value
0.5	25/429	25/394	1.11 (0.62, 1.99)	0.7227	25/418	1.07 (0.60, 1.92)	0.8158	27/429	19/397	0.76(0.41, 1.41)	0.3857	26/433	0.94 (0.53, 1.66)	0.8361
1	74/446	70/406	1.06 (0.74, 1.53)	0.7429	70/437	0.99 (0.69, 1.43)	0.9743	64/443	66/414	1.14 (0.78, 1.67)	0.5088	76/450	1.20(0.83, 1.74)	0.3359
1.5	99/447	119/413	1.47 (1.07, 2.01)	0.0168	124/444	1.41 (1.03, 1.93)	0.0301	98/449	110/422	1.29(0.94, 1.78)	0.1178	127/455	1.39(1.02, 1.89)	0.0398
2	126/454	162/420	1.70 (1.27, 2.28)	0.0003	169/448	1.63 (1.22, 2.17)	0.0008	125/456	158/434	1.37 (1.02, 1.83)	0.0355	180/463	1.65(1.25, 2.20)	0.0005
3	163/454	209/420	1.83 (1.39, 2.41)	<0.0001	226/448	1.86 (1.42, 2.44)	<0.0001	166/456	207/434	1.58(1.21, 2.08)	0.0009	252/463	2.06(1.58, 2.70)	<0.0001
4	202/454	251/420	1.94 (1.47, 2.55)	<0.0001	288/448	2.33 (1.77, 3.06)	<0.0001	214/456	260/434	1.70(1.29, 2.22)	0.0001	304/463	2.14(1.64, 2.81)	<0.0001
6	260/454	301/420	1.96 (1.47, 2.62)	0.0001	323/448	2.00 (1.51, 2.65)	<0.0001	254/456	315/434	2.12(1.60, 2.83)	<0.0001	334/463	2.04(1.54, 2.70)	<0.0001
8	298/454	333/420	2.08 (1.52, 2.83)	<0.0001	357/448	2.15 (1.58, 2.92)	<0.0001	295/456	332/434	1.76(1.31, 2.37)	0.0002	363/463	1.94(1.44, 2.61)	<0.0001
24	362/454	367/420	1.79 (1.23, 2.60)	0.0022	380/448	1.47 (1.03, 2.08)	0.0319	364/456	363/434	1.28(0.90, 1.80)	0.1646	403/463	1.68(1.17, 2.40)	0.0046
48	392/454	376/420	1.37 (0.90, 2.07)	0.1420	393/448	1.16 (0.78, 1.71)	0.4702	390/456	369/434	0.95(0.65, 1.38)	0.7966	411/463	1.31(0.88, 1.94)	0.1785

N1 = Number of patients with non-missing postdose pain severity assessment at or prior to the timepoint in the modified intent-to-treat population.
Missing data was handled using last observation carried forward.
Includes data from all participants, including those who took rescue medication or an optional second dose of trial treatment.
Odds ratio (95% CI) and p-value are based on logistic regression with treatment group, historical triptan response, use of medication for migraine prevention, and baseline headache severity as explanatory variables.
Percentages calculated as 100 x (n/N1).